-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Amarin Co. Plc (NASDAQ:AMRN) Short Interest Update
Amarin Co. Plc (NASDAQ:AMRN) Short Interest Update
Amarin Co. plc (NASDAQ:AMRN – Get Rating) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 9,560,000 shares, a drop of 24.8% from the August 31st total of 12,720,000 shares. Based on an average trading volume of 3,570,000 shares, the short-interest ratio is currently 2.7 days.
Amarin Stock Performance
Shares of AMRN stock opened at $1.10 on Friday. The stock has a market capitalization of $443.53 million, a P/E ratio of -4.40 and a beta of 1.87. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.89. Amarin has a fifty-two week low of $1.04 and a fifty-two week high of $5.24.
Get Amarin alerts:Amarin (NASDAQ:AMRN – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $94.44 million during the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. The company's revenue for the quarter was down 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS. On average, research analysts forecast that Amarin will post -0.36 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded shares of Amarin from a "sell" rating to a "hold" rating in a research report on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Amarin currently has an average rating of "Hold" and an average target price of $2.50.Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Creative Planning grew its holdings in shares of Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 6,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in Amarin during the 1st quarter worth approximately $31,000. Winthrop Advisory Group LLC acquired a new position in Amarin during the 1st quarter worth approximately $34,000. Kalos Management Inc. acquired a new position in Amarin during the 1st quarter worth approximately $37,000. Finally, Advisor Resource Council acquired a new position in Amarin during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 34.15% of the company's stock.
About Amarin
(Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- This Small-Cap Healthcare Name Is Outperforming Its Index
- 2 Casino Stocks Worth Taking a Look At
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
Amarin Co. plc (NASDAQ:AMRN – Get Rating) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 9,560,000 shares, a drop of 24.8% from the August 31st total of 12,720,000 shares. Based on an average trading volume of 3,570,000 shares, the short-interest ratio is currently 2.7 days.
愛馬林股份有限公司(納斯達克:AMRN-GET評級)是空頭股數9月份大幅下跌的目標。截至9月15日,空頭股數共有9,560,000股,較8月31日的12,720,000股減少24.8%。以平均成交量3,57萬股計算,目前短息比為2.7天。
Amarin Stock Performance
Amarin股票表現
Shares of AMRN stock opened at $1.10 on Friday. The stock has a market capitalization of $443.53 million, a P/E ratio of -4.40 and a beta of 1.87. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.89. Amarin has a fifty-two week low of $1.04 and a fifty-two week high of $5.24.
AMRN股票上週五開盤報1.10美元。該股市值為4.4353億美元,市盈率為-4.40,貝塔係數為1.87。該公司的50日移動均線價格為1.32美元,200日移動均線價格為1.89美元。Amarin的52周低點為1.04美元,52周高位為5.24美元。
Amarin (NASDAQ:AMRN – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $94.44 million during the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. The company's revenue for the quarter was down 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS. On average, research analysts forecast that Amarin will post -0.36 EPS for the current fiscal year.
愛馬林(納斯達克代碼:AMRN-GET Rating)上一次公佈季度收益數據是在8月3日星期三。這家生物製藥公司公佈了該季度每股收益(0.18美元),低於分析師普遍預期的(0.07美元)至(0.11美元)。該業務本季度營收為9444萬美元,而分析師預期為8821萬美元。Amarin的淨利潤率為負21.05%,股本回報率為負13.63%。該公司本季度營收同比下降38.9%。去年同期,該公司公佈的每股收益為0.02美元。研究分析師平均預測,阿馬林本財年每股收益將達到0.36歐元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors have recently made changes to their positions in the business. Creative Planning grew its holdings in shares of Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 6,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in Amarin during the 1st quarter worth approximately $31,000. Winthrop Advisory Group LLC acquired a new position in Amarin during the 1st quarter worth approximately $34,000. Kalos Management Inc. acquired a new position in Amarin during the 1st quarter worth approximately $37,000. Finally, Advisor Resource Council acquired a new position in Amarin during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 34.15% of the company's stock.
機構投資者最近對他們在該業務中的頭寸進行了調整。創意策劃在第二季度增持了66.4%的Amarin股票。Creative Planning現在擁有這家生物製藥公司17,285股股票,價值26,000美元,上個季度又購買了6,900股。Quantbot Technologies LP在第一季度收購了阿馬林的一個新頭寸,價值約3.1萬美元。温斯羅普諮詢集團在第一季度收購了阿馬林的一個新頭寸,價值約3.4萬美元。Kalos Management Inc.在第一季度收購了阿馬林的一個新頭寸,價值約3.7萬美元。最後,顧問資源委員會在第二季度在阿馬林獲得了一個價值約3.7萬美元的新職位。機構投資者和對衝基金持有該公司34.15%的股票。
About Amarin
關於阿瑪林
(Get Rating)
(獲取評級)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Amarin Corporation plc是一家制藥公司,在美國、德國、加拿大、黎巴嫩和阿拉伯聯合酋長國從事心血管疾病治療藥物的開發和商業化。它的主要產品是Vascepa,一種僅限處方的omega-3脂肪酸產品,用作飲食的輔助產品,用於降低患有嚴重高甘油三酯血癥的成年患者的甘油三酯水平。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- This Small-Cap Healthcare Name Is Outperforming Its Index
- 2 Casino Stocks Worth Taking a Look At
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- 免費獲取StockNews.com關於Amarin的研究報告(Amrn)
- Humana證明垂直整合的醫療保健工作
- 關於這個熊市,Cintas能教給投資者什麼?
- 這家小盤股醫療保健公司的表現好於其指數
- 值得一看的2只賭場股票
- 黑莓股價下跌,業績再次不温不火
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿馬林日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Amarin和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧